Neurology

Amplexa is uniquely specialized in epilepsy having developed our panels in close collaboration with researchers from Filadelfia, the Danish Epilepsy Centre and from King's College Hospital. Rikke Steensbjerre Møller, PhD, from Filadelfia, and Prof Deb Pal from King's College Hospital London, are part of Amplexa Genetic's Advisory Board.

In the field of epilepsy Amplexa currently offers three targeted Next Generation Sequencing (tNGS) panel:

Suitable
for diagnosis of epilepsy and epileptic encephalopathies, in particular those
with early onset of seizures (up to ~3 years of age). For neonatal onset of seizures,
positive findings are made in approximately 60% of patients. The panel also
contains genes for familial focal epilepsies and epilepsies with later age of
onset of seizures.

This
test is relevant for autisme and autism spectrum disorders without epilepsy as
well as mental retardation, intellectual disability and combinations thereof. The test includes genes
from tests mentioned above (CHE, PME, BMF) plus an additional 400 genes.

We can extract single genes from our panels or create virtual panels customized to your needs, by blinding ourselves to the genes you wish to leave out. This way, we customize our analysis to your needs. Prices vary accordingly.

Looking for a specific gene or phenotype? Use our selector in the center of our front page.